ArticleInternational journal of hematology2023

Interim analysis of post-marketing surveillance of ravulizumab for paroxysmal nocturnal hemoglobinuria in Japan.

Kensuke Usuki et al.PubMed ↗Publisher ↗

No numbers read from the abstract.